DE60230877D1 - Behandlung von muskeldystrophien und verwandter erkrankungen - Google Patents

Behandlung von muskeldystrophien und verwandter erkrankungen

Info

Publication number
DE60230877D1
DE60230877D1 DE60230877T DE60230877T DE60230877D1 DE 60230877 D1 DE60230877 D1 DE 60230877D1 DE 60230877 T DE60230877 T DE 60230877T DE 60230877 T DE60230877 T DE 60230877T DE 60230877 D1 DE60230877 D1 DE 60230877D1
Authority
DE
Germany
Prior art keywords
abnormal
treatment
related diseases
activity
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230877T
Other languages
English (en)
Inventor
Justin R Fallon
Michael Rafii
Beth Mckechnie
Mark Bowe
Mary Lynn Mercado
Hiroki Hagiwara
Alison Amenta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brown University Research Foundation Inc
Original Assignee
Brown University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University Research Foundation Inc filed Critical Brown University Research Foundation Inc
Application granted granted Critical
Publication of DE60230877D1 publication Critical patent/DE60230877D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60230877T 2001-08-15 2002-08-15 Behandlung von muskeldystrophien und verwandter erkrankungen Expired - Lifetime DE60230877D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31255101P 2001-08-15 2001-08-15
PCT/US2002/026201 WO2003015615A2 (en) 2001-08-15 2002-08-15 Treatment of muscular dystrophies and related disorders

Publications (1)

Publication Number Publication Date
DE60230877D1 true DE60230877D1 (de) 2009-03-05

Family

ID=23211978

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230877T Expired - Lifetime DE60230877D1 (de) 2001-08-15 2002-08-15 Behandlung von muskeldystrophien und verwandter erkrankungen

Country Status (7)

Country Link
US (3) US7759314B2 (de)
EP (1) EP1423133B1 (de)
AT (1) ATE420654T1 (de)
AU (1) AU2002323217B2 (de)
CA (1) CA2455884C (de)
DE (1) DE60230877D1 (de)
WO (1) WO2003015615A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US7612038B2 (en) * 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
ATE420654T1 (de) * 2001-08-15 2009-01-15 Univ Brown Res Found Behandlung von muskeldystrophien und verwandter erkrankungen
US8846003B2 (en) 2008-03-27 2014-09-30 Symic Biomedical, Inc. Collagen-binding synthetic peptidoglycans, preparation, and methods of use
US20110224128A1 (en) * 2009-04-13 2011-09-15 Anne Whalen Methods and compositions for treatment of muscular dystrophy
KR100983182B1 (ko) * 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
CA2774999A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
JP6339367B2 (ja) * 2010-05-17 2018-06-06 ブラウン ユニバーシティ バイグリカン変異体および関連する治療薬および使用方法
WO2012092299A1 (en) * 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
BR112013030086A2 (pt) 2011-05-24 2022-03-03 Purdue Research Foundation Peptideoglicanos sintéticos que se ligam ao ácido hialurônico, matriz de colágeno engenheirada e seus usos
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
MX2015012608A (es) 2013-03-15 2016-07-06 Symic Biomedical Inc Peptidos sinteticos de union a matriz extracelular.
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
AU2015255752B2 (en) 2014-05-08 2020-07-23 Immunoforge Co., Ltd. Methods and compositions for treating Cystic Fibrosis
US10688156B2 (en) 2015-02-09 2020-06-23 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2018067449A1 (en) * 2016-10-05 2018-04-12 Bio-Techne Corporation Methods and kits for assaying endoglycosidase activity
EP3648774A4 (de) 2017-07-07 2021-04-21 Symic IP, LLC Synthetische biokonjugate
WO2020055240A1 (en) * 2018-09-10 2020-03-19 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Musk inhibition
US20230304012A1 (en) * 2019-10-16 2023-09-28 Brown University Muscle regeneration and growth

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) * 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5340934A (en) * 1989-11-03 1994-08-23 The United States Of Americas As Represented By The Secretary Of Health & Human Services CDNA sequences of human bone matrix proteins
DE69228700T2 (de) 1991-12-04 1999-09-09 La Jolla Cancer Research Foundation Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
US5955265A (en) 1992-02-06 1999-09-21 Massachusetts Institute Of Technology DNA sequence encoding the myotonic dystrophy gene and uses thereof
DE69420024T2 (de) 1993-08-10 2000-02-24 W.L. Gore & Associates, Inc. Zelleinkapselungsvorrichtung
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
WO1995013298A1 (en) 1993-11-10 1995-05-18 Worcester Foundation For Experimental Biology Agrin receptor
AU6926194A (en) 1994-05-09 1995-11-29 Boehringer Mannheim Gmbh Use of chondroitin sulphate proteoglycans for protection of neurons
US5882868A (en) 1997-04-14 1999-03-16 The Nemours Foundation Method of diagnosing spinal muscular atrophy
AU4449900A (en) * 1999-03-17 2000-10-04 Entremed, Inc Compositions and methods of use of ldl-like receptor ligands for the treatment of cancer and angiogenic-based disease
WO2001036475A2 (en) * 1999-11-18 2001-05-25 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US6864236B1 (en) * 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
ATE420654T1 (de) * 2001-08-15 2009-01-15 Univ Brown Res Found Behandlung von muskeldystrophien und verwandter erkrankungen
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
WO2008100789A2 (en) 2007-02-16 2008-08-21 Benaroya Research Institute At Virginia Mason Compositions and methods for altering elastogenesis
JP6339367B2 (ja) 2010-05-17 2018-06-06 ブラウン ユニバーシティ バイグリカン変異体および関連する治療薬および使用方法

Also Published As

Publication number Publication date
WO2003015615A2 (en) 2003-02-27
EP1423133A4 (de) 2006-03-01
WO2003015615A3 (en) 2003-11-13
ATE420654T1 (de) 2009-01-15
AU2002323217B2 (en) 2008-04-10
US7759314B2 (en) 2010-07-20
EP1423133B1 (de) 2009-01-14
US20110053854A1 (en) 2011-03-03
US20050043221A1 (en) 2005-02-24
CA2455884A1 (en) 2003-02-27
WO2003015615A9 (en) 2003-08-07
CA2455884C (en) 2015-09-22
US20150182589A1 (en) 2015-07-02
US8822418B2 (en) 2014-09-02
EP1423133A2 (de) 2004-06-02

Similar Documents

Publication Publication Date Title
DE60230877D1 (de) Behandlung von muskeldystrophien und verwandter erkrankungen
ATE325343T1 (de) Diagnose und behandlung von arthritischen erkrankungen
DE602005019874D1 (de) Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors
DE60236206D1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
NO20010446L (no) Substituert anilidforbindelser og metoder
TR200103104T2 (tr) Glukortikoid alıcı modülatörleri
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
ATE443699T1 (de) Pyridine zur behandlung von verletztemsäugetiernervengewebe
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE352311T1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
WO2003070195A3 (en) Biglycan and related therapeutics and methods of use
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
WO2001036475A3 (en) Biglycan and related therapeutics and methods of use
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition